Global Pneumococcal Vaccines
Market Report
2024
Pneumococcal Vaccines Market Report 2024 (Global Edition)
Delivery Includes:- Market Timeline 2019 till 2031, Market Size, Revenue/Volume Share, Forecast and CAGR, Competitor Analysis, Regional Analysis, Country Analysis, Segment Analysis, Market Trends, Drivers, Opportunities, Restraints, ESG Analysis, Porters Analysis, PESTEL Analysis, Market Attractiveness, Patent Analysis, Technological Trend, SWOT Analysis, COVID-19 Analysis, Consumer Behavior Analysis, etc.
The base year for the calculation is 2023 and 2019 to 2023 will be historical period. The year 2024 will be estimated one while the forecasted data will be from year 2025 to 2031. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
| Share your contact details to receive free updated sample copy/pages of the recently published edition of Pneumococcal Vaccines Market Report 2024.
Global Pneumococcal Vaccines Market Report 2024 Market Size Split by Vaccine Type (Pneumococcal Polysaccharide Vaccines, Pneumococcal Conjugate Vaccines), by Product Type (Pneumovax 23, Synflorix, Pre...
According to Cognitive Market Research, the Global Pneumococcal Vaccines Market Size will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.
- The Pneumococcal Vaccines market will expand significantly by XX% CAGR between 2024 and 2031.
- The Pneumococcal Conjugate vaccine type accounts for the largest market share and is anticipated to a healthy growth over the approaching years.
- The usage of the Prevenar13 pneumococcal vaccine holds the largest market share compared to others.
- By Distribution channel, the public health agencies hold the largest market share compared to others.
- North-America region dominated the market and accounted for the highest revenue of XX% in 2022 and it is projected that it will grow at a CAGR of XX% in the future.
| Base Year | 2023 |
| Historical Data Time Period | 2019-2023 |
| Forecast Period | 2024-2031 |
| Global Market Size | 121212 |
| Country Market Size | 121212 |
| North Americ Market Size | 121212 |
| Europe Market Size | 121212 |
| Asia Pacific Market Size | 121212 |
| South America Market Size | 121212 |
| Middle East and Africa Market Size | 121212 |
Market Drivers:
| |
Market Restrains:
| |
Market Trends:
| |
| Market Split by Vaccine Type |
|
| Market Split by Product Type |
|
| Market Split by Sector |
|
| Market Split by Distribution Channel |
|
| Market Split by Conclusion | |
| List of Competitors |
|
| Regional Analysis |
|
Country Analysis |
|
Key Qualitative Information Covered |
|
Report scope is customizable as we have a huge database of Pneumococcal Vaccines industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Pneumococcal Vaccines Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Pneumococcal Vaccines Market Report Description
Introduction to the Global Pneumococcal Vaccines Market
Pneumococcal vaccination is an important healthcare measure that can substantially reduce the burden of pneumococcal disease in vaccinated individuals and in the population. Pneumonia can be caused by viruses, bacteria, or fungi and can be prevented by immunization, adequate nutrition, and by addressing environmental factors. It is a form of acute respiratory infection that affects the lungs. Pneumococcal vaccination is normally a routine part of infant and childhood immunization schedules worldwide as children are more likely to get infected before reaching the age of 5 years.
Pneumococcus bacteria is the leading cause of severe pneumonia and bacterial meningitis worldwide. Pneumonia kills around 740,000 children of age below 5 years, making it the single largest infectious cause of death in children. (Source: https://www.gavi.org/vaccineswork/routine-vaccines-extraordinary-impact-pneumococcus)
Pneumonia accounts for 14% of all deaths of children under 5 years old, killing nearly 740,180 children in 2019. (Source: https://www.who.int/news-room/fact-sheets/detail/pneumonia)
Hence, the Pneumococcal Vaccines Market is expected to experience significant growth due to the increased awareness about pneumonia and increased product launches to cure the same.
Factors Affecting the Growth of the Pneumococcal Vaccines Market
The rising cases of pneumonia are directly driving the demand for pneumococcal vaccines in the market.
Pneumococcal disease is caused by the bacterium Streptococcus pneumoniae, as called pneumococcus. There are more than 100 subtypes and most of the subtypes can cause disease, but only a few produce the majority of invasive pneumococcal infections. Pneumonia is the single largest infectious cause of death in children worldwide. It causes more than a million hospitalizations and more than 50,000 deaths each year. (Source: https://www.lung.org/lung-health-diseases/lung-disease-lookup/pneumonia/five-facts-you-should-know)
Around 4,000 cases of pneumococcal bacteremia occur every year in the United States. Bacteremia is the most common clinical presentation among children aged two years and younger, accounting for 70% of invasive disease in this group. Additionally, there are an estimated 2,000 cases of pneumococcal meningitis every year. Considering the criticality, pneumococcal disease is a serious disease that causes much sickness and death. Around, 30,300 cases and 3,250 deaths from invasive pneumococcal diseases are estimated to have occurred in the United States in 2019.
(Source: https://www.immunize.org/wp-content/uploads/catg.d/p4213.pdf)
Furthermore, pneumonia accounts for around 14% of all deaths of children under 5 years old, killing nearly 740,180 children in 2019. (Source: https://www.who.int/news-room/fact-sheets/detail/pneumonia)
Certain medical concerns associated with the pneumococcal vaccine may restrict the Pneumococcal Vaccines Market growth.
Normally, most people who get a pneumococcal vaccine do not have any serious problems with it; however, with any medicines and vaccines, chances of being caught to certain side effects are always there. The side effects tend to be mild and go away on their own within a few days; however, some serious reactions might be possible.
Mild problems related to PCV15, PCV20, or PPSV23 can include Redness, swelling, pain, or tenderness where the shot was given, Fever or chills, Loss of appetite, Fussiness, Feeling tired, Headache, Muscle ache, or joint pain. These symptoms may lead people to avoid the vaccination, resulting in the restriction in the market growth. (Source: https://www.cdc.gov/vaccines/vpd/pneumo/public/index.html)
The most common side effects from pneumococcal vaccines are mild and last for 1 or 2 days. The chances of getting severe allergic reactions are very rare.; however, such independent risk factors can restrict the market growth for pneumococcal vaccines.
An innovative financial mechanism by the Pneumococcal Advance Market Commitment can be considered as an opportunity for vaccine makers to produce vaccines at affordable prices.
Each year, pneumococcal disease takes the lives of half a million children under five years of age, making it the leading vaccine-preventable cause of death among young children. The most effective estimate to prevent these deaths is to ensure access to effective, safe, and affordable vaccines. To make this happen, a pneumococcal Advance Market Commitment (AMC) has been designed to protect children against pneumococcal disease.
This financial commitment offers an innovative funding mechanism with the help of donor commitments, that can benefit vaccine makers to produce suitable and affordable vaccines for the world’s poorest countries accelerating the global roll-out of a vaccine against the world’s leading cause of child deaths. These countries will then be able to plan for immunisation programmes knowing that vaccines will be available rapidly, in the quantities they need and at affordable prices. As a result, the PCV AMC pilot likely was successful at driving higher coverage of PCV than has been seen with other antigens. This increased coverage led to more lives saved.
Such practices can help the producers to reach and expand their market even in the least developed and poor countries, leading to a rise in market growth.
(Source: https://www.gavi.org/investing-gavi/innovative-financing/pneumococcal-amc/about-pneumococcal-amc)
How did the COVID–19 Impact the Pneumococcal Vaccines Market?
The outbreak of coronavirus disease resulted in a decline in global vaccination efforts due to the burden on health systems and community resistance to epidemic control measures. The situation was further worsened by the lockdowns of receiving countries where airports were closed. The outbreak not only collapsed the airline industry, but the vaccine shipments and other critical deliveries were also heavily impacted due to a dramatic decline in the available flights. However, vaccines were still recommended for vulnerable populations to prevent severe pneumonia conditions. Some other studies also reported that during the coronavirus disease 2019 pandemic, routine immunization activities were at risk of disruption due to the burden on the health system, reduced need for vaccination owing to physical distancing requirements, and community resistance.
The COVID-19 pandemic did impact the world; however, it also resulted in increased awareness of the importance of vaccination among women, and adults. COVID-19-induced immunological dysfunction is still a high-risk factor for pneumococcal illness. COVID-19 is regarded as a key risk factor for pneumococcal pneumonia and invasive pneumococcal disease. As a result, pneumococcal vaccination became more important during the COVID-19 pandemic and the market started growing significantly.
Recent Developments
• 3rd April 2024: Manipal Hospitals announced its collaboration with Pfizer, an American multinational pharmaceutical and biotechnology corporation, to improve patient care and advocate for adult vaccination.
(Source: https://www.thehindu.com/news/national/andhra-pradesh/manipal-hospitals-collaborates-with-pfizer-to-improve-patient-care/article68025462.ece)
• 20th December 2023: The U.S. Food and Drug Administration (FDA) accepted Merck’s new biologics license application (BLA). The vaccine is intended to prevent invasive pneumococcal disease and pneumococcal pneumonia in adults.
(Source: https://www.pharmaceutical-technology.com/news/fda-merck-pneumococcal-vaccine/?cf-view)
• 27th July 2023: Merck, known as MSD announced positive topline results from two Phase 3 trials evaluating V116, the company’s investigational 21-valent pneumococcal conjugate vaccine in vaccine-naïve and previously vaccinated individuals.
(Source: https://www.merck.com/news/merck-announces-v116-an-investigational-21-valent-pneumococcal-conjugate-vaccine-specifically-designed-for-adults-met-key-immunogenicity-and-safety-endpoints-in-two-phase-3-trials/)
• 27th April 2023: Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved PREVNAR 20® (20-valent Pneumococcal Conjugate Vaccine) for the prevention of invasive pneumococcal disease (IPD).
(Source: https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-prevnar-20r-pfizers-20-valent-pneumococcal)
• 16th August 2022: GSK plc announced that it has completed the acquisition of Affinivax, Inc., a clinical-stage biopharmaceutical company based in Cambridge. Affinivax has pioneered the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines.
(Source: https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-affinivax-inc/)
• 12th August 2022: Pfizer announced positive top-line results from its pivotal U.S. Phase 3 study of 20-valent pneumococcal conjugate vaccine in infants.
(Source: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-3-study-20)
We have various report editions of Pneumococcal Vaccines Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
Competitive Landscape of the Pneumococcal Vaccine Market
To sustain the increasing competition and attain new heights in providing healthcare services, companies are leveraging advancements in technology to innovate and launch new products to gain a competitive advantage. Companies are continuously investing in research and development activities to stay upgraded as per the changing consumer preferences, and market demand, and offer quality treatment options.
Top Companies Market Share in Pneumococcal Vaccines Industry: (In no particular order of Rank)
- Pfizer Inc.
- GlaxoSmithKline plc
- Merck & Co. Inc.
- Serum Institute of India Pvt. Ltd
- Biological E. Limited
- Abbott
- Sanofi Pasteur SA
- Wyeth Pharmaceuticals LLC
- Walvax Biotechnology Co. Ltd.
- Sk Bioscience.
- Panacea Biotec Limited.
- Confidential Data
- Access The Paid Version
- Data Hidden
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
Which Region will dominate the Pneumococcal Vaccines Market in 2024?
According to Cognitive Research, North-America region dominated the market and accounted for the highest revenue of XX% in 2022 and it is projected that it will grow at a CAGR of XX% in the future. The well-developed healthcare infrastructure, the increasing investments in vaccine development, and the rising prevalence of pneumonia within the region are driving the market growth in the North American region. The continuous upgradation and innovation in technological and health infrastructure with the support of government bodies are propelling the market growth.
For instance, The U.S. Food and Drug Administration (FDA) accepted Merck’s new biologics license application (BLA). The vaccine is intended to prevent invasive pneumococcal disease and pneumococcal pneumonia in adults.
(Source: https://www.pharmaceutical-technology.com/news/fda-merck-pneumococcal-vaccine/?cf-view)
Furthermore, the rising investments in vaccine development are expanding the growth scope for the market players in the region.
Which Region is Expanding at the Fastest CAGR?
The Asia Pacific region is expected to grow with the fastest CAGR during the forecast period. The regional growth is attributed to the high prevalence of pneumococcal disease leading to a high scope of vaccine supply. Also, the region has been witnessing progress in expanding access to immunizations. Another factor fuelling the market growth is the rising population leading to a high number of child population that are to be provided pneumococcal vaccination as mandatory immunization, government initiatives in spreading awareness about the vaccines, and increased healthcare expenditure to improve infrastructure.
The current report Scope analyzes Pneumococcal Vaccines Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
- North America (United States, Canada, Mexico)
- Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
- Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
- South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
- Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)
Pneumococcal Vaccines Market Share (%) by Region (2019-2031)
The above graph is for illustrative purposes only.
To learn more about geographical trends request the free sample pages.
Get Free Sample
North America Pneumococcal Vaccines Market
According to Cognitive Market Research, the North America Pneumococcal Vaccine Market Size will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.
Europe Pneumococcal Vaccines Market
According to Cognitive Market Research, the Europe Pneumococcal Vaccine Market Size will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.
Asia Pacific Pneumococcal Vaccines Market
According to Cognitive Market Research, the Asia Pacific Pneumococcal Vaccine Market Size will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.
South America Pneumococcal Vaccines Market
According to Cognitive Market Research, the South America Pneumococcal Vaccine Market Size will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.
Middle East and Africa Pneumococcal Vaccines Market
According to Cognitive Market Research, the Middle East and Africa Pneumococcal Vaccine Market Size will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.
An increase in the number of pneumococcal diseases in the region has propelled the growth of the Pneumococcal Vaccines Market. Pneumonia is a leading cause of hospitalization and death in children and adults in South Africa.
Pneumococcal Vaccines Market Analysis
Global Pneumococcal Vaccines Market Report 2024 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Pneumococcal Vaccines Industry growth. Pneumococcal Vaccines market has been segmented with the help of its Vaccine Type, Product Type Sector, and others. Pneumococcal Vaccines market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
By Vaccine type, the market is dominated by Pneumococcal Conjugate Vaccines (PCV). These vaccines can protect children from Streptococcus pneumoniae, which is the most common cause of severe bacterial pneumonia among children. It is already been used in the national immunization program of 146 countries as of June 2020. PCV has demonstrated effectiveness in reducing the incidence and severity of pneumonia and other lower respiratory infections in children. PCVs are the vaccines that are generally recommended for infants younger than two years of age as Pneumococcal Polysaccharide Vaccines (PPSV) are comparatively less effective for this age group.
Pneumococcal Vaccines Market Share (%) by Vaccine Type in 2019-2031
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Pneumococcal Vaccines Industry. Request a Free Sample PDF!
Among all the product types, Prevenar 13 is reported to dominate the pneumococcal vaccine market. Prevenar 13 is a vaccine available as a suspension for injection that contains parts from 13 different types of the bacterium Streptococcus pneumoniae. It is normally used to protect children aged between six weeks and 17 years against invasive disease, pneumonia, and acute otitis media caused by Streptococcus pneumoniae. This vaccine helps the body make its antibodies which protect against such diseases. As the name goes, Prevenar 13 is only capable of protecting against disease caused by thirteen strains of Streptococcus pneumoniae bacteria included in the vaccine. Additionally, as per studies, Prevenar 13 led to an increase in antibody production following booster vaccinations.
Pneumococcal Vaccines Market Share (%) by Product Type in 2019-2031
2019
2023
2031
The above Graph is for representation purposes only. This chart does not depict actual Market share.
To learn more about market share request the free sample pages.
Get Free Sample
Pneumococcal Vaccines Sector Segment Analysis
- Public
- Private
Pneumococcal Vaccines Distribution Channel Segment Analysis
Based on distribution channels, the market is reported to be dominated by public health agencies. They have the largest hold on the purchases of vaccines made by organizations like GAVI, WHO, UNICEF, and others. These organizations purchase vaccines in bulk quantities and distribute them across the geographies.
GAVI-supported countries immunize more than 215 million children across 60 lower-income countries against pneumococcal disease in 2019.
In the same year, pneumococcal vaccine coverage in Gavi-supported countries was higher than the worldwide average of 49% in 2019.
(Source: https://www.gavi.org/types-support/vaccine-support/pneumococcal)
- Pharmacies
- Community clinics
- Public Health agencies
- Others
Author's Detail
Manjiri KanhereSenior Research Associate at Cognitive Market Research
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over three years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies.
In her current role, Manjiri handles the market research related to Pharma and healthcare industry. Her passion lies in utilizing innovative approaches to distill complex information into strategic insights that empower organizations to make informed decisions.Manjiri remains an invaluable asset in the dynamic landscape of market research.
Author's Conclusion
With the help of the above study about the Pneumococcal Vaccines Market, it can be concluded that the market for Pneumococcal Vaccine worldwide is expected to develop significantly shortly. From the report, one can understand and infer the market dynamics, segmentations, status and trends, and key players in the market. It provides data regarding various topics such as market dimensions, prevailing trends, competitive landscape, and the outlook for prospective expansion. This allows the reader to understand and access reliable data about the market and industry.
Frequently Asked Questions (FAQs)
Please note, we have not disclose, all the sources consulted/referred during a market study due to confidentiality and paid service concern. However, rest assured that upon purchasing the service or paid report version, we will release the comprehensive list of sources along with the complete report and we also provide the data support where you can intract with the team of analysts who worked on the report.
Latest News about Pneumococcal Vaccines Market
https://www.gavi.org/vaccineswork/routine-vaccines-extraordinary-impact-pneumococcus
https://www.lung.org/lung-health-diseases/lung-disease-lookup/pneumonia/five-facts-you-should-know
Sources from Pharma & Healthcare Industry
- https://en.wikipedia.org/wiki/American_Society_for_Pharmacy_Law
- https://en.wikipedia.org/wiki/American_Society_of_Consultant_Pharmacists
- https://en.wikipedia.org/wiki/American_Society_of_Health-System_Pharmacists
- https://www.apsm-uk.com/
- https://en.wikipedia.org/wiki/Australasian_College_of_Pharmacy
- https://en.wikipedia.org/wiki/American_Association_of_Colleges_of_Pharmacy
- https://en.wikipedia.org/wiki/American_College_of_Clinical_Pharmacy
- https://en.wikipedia.org/wiki/American_Pharmacists_Association
- https://www.bio.org/
- https://en.wikipedia.org/wiki/Canadian_Pharmacists_Association
- https://en.wikipedia.org/wiki/Canadian_Society_of_Hospital_Pharmacists
- https://en.wikipedia.org/wiki/Chinese_Pharmaceutical_Association
- https://en.wikipedia.org/wiki/American_Association_of_Psychiatric_Pharmacists
- https://en.wikipedia.org/wiki/Danish_Association_of_Pharmaconomists
- https://en.wikipedia.org/wiki/EPhEU
- https://www.fda.gov/
- https://www.gmc-uk.org/
- https://www.ifpma.org/
- https://www.fip.org/
- https://en.wikipedia.org/wiki/International_Pharmaceutical_Students%27_Federation
- https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
- https://en.wikipedia.org/wiki/National_Pharmacy_Association
- https://en.wikipedia.org/wiki/Norwegian_Pharmacy_Association
- https://en.wikipedia.org/wiki/Canadian_Pharmacists_Journal#History
- https://en.wikipedia.org/wiki/Pakistan_Pharmacists_Association
- https://en.wikipedia.org/wiki/Pharmaceutical_Association_of_Mauritius
- https://en.wikipedia.org/wiki/Pharmaceutical_Group_of_the_European_Union
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_Australia
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_New_Zealand
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_Northern_Ireland
- https://en.wikipedia.org/wiki/Professional_Compounding_Centers_of_America
- https://en.wikipedia.org/wiki/Royal_Pharmaceutical_Society
- https://www.aaps.org/home
- https://www.bioindustry.org/
- https://www.controlledreleasesociety.org/
- https://www.efpia.eu/
- https://www.epemed.org/online/www/content/ENG/index.html
- https://icr-global.org/
- https://ispe.org/
- https://en.wikipedia.org/wiki/Pharmaceutical_Association_of_Israel
- https://www.phrma.org/
- https://en.wikipedia.org/wiki/The_Pharmacy_Guild_of_Australia
- https://en.wikipedia.org/wiki/The_Society_of_Hospital_Pharmacists_of_Australia
- https://en.wikipedia.org/wiki/Healthcare_industry
- https://www.pharma-iq.com/business-development/articles/top-50-pharmaceutical-blogs-and-publications
- https://www.pharmatimes.com/news
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967517/
- https://www.cbo.gov/publication/57126
- http://: https://www.who.int/tools/atc-ddd-toolkit/data
- https://www.oecd.org/els/health-systems/health-data.htm
- https://www.bls.gov/ooh/healthcare/home.htm
- https://data.worldbank.org/topic/8
- https://www.statnews.com/about/
- https://www.health.pa.gov/topics/HealthStatistics/Pages/health-statistics.aspx
- https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Healthcare_expenditure_statistics
- https://www.cdc.gov/nchs/index.htm
- https://www.aha.org/statistics/fast-facts-us-hospitals
- https://www.census.gov/library/publications/2021/demo/p60-274.html
- https://www.adb.org/what-we-do/sectors/health/main
Pneumococcal Vaccines Market Report Table of Content
Disclaimer:
- This is just a redacted sample pages of the actual deliverable report and only for representative purposes
- Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
- The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
- Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
- If applicable; On Request Volume Data will also be provided (at an Additional Cost).
| Vaccine Type | Pneumococcal Polysaccharide Vaccines, Pneumococcal Conjugate Vaccines |
| Product Type | Pneumovax 23, Synflorix, Prevnar 13, Others |
| Sector | Public, Private |
| Distribution Channel | Pharmacies, Community clinics, Public Health agencies, Others |
| Conclusion | |
| List of Competitors | Pfizer Inc., GlaxoSmithKline plc, Merck & Co. Inc., Serum Institute of India Pvt. Ltd, Biological E. Limited, Abbott, Sanofi Pasteur SA, Wyeth Pharmaceuticals LLC, Walvax Biotechnology Co. Ltd., Sk Bioscience., Panacea Biotec Limited. |
This chapter will help you gain GLOBAL Market Analysis of Pneumococcal Vaccines. Further deep in this chapter, you will be able to review Global Pneumococcal Vaccines Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
-
1.1 Global Pneumococcal Vaccines Market Size, Trend Analysis 2019 - 2031
-
1.2 Global Pneumococcal Vaccines Market Size By Regions 2019 - 2031
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
-
1.2.1 Global Pneumococcal Vaccines Revenue Market Size By Region
-
-
1.3 Global Pneumococcal Vaccines Market Size By Vaccine Type 2019 -2031
-
1.3.1 Pneumococcal Polysaccharide Vaccines Market Size
-
1.3.2 Pneumococcal Conjugate Vaccines Market Size
-
-
1.4 Global Pneumococcal Vaccines Market Size By Product Type 2019 -2031
-
1.4.1 Pneumovax 23 Market Size
-
1.4.2 Synflorix Market Size
-
1.4.3 Prevnar 13 Market Size
-
1.4.4 Others Market Size
-
-
1.5 Global Pneumococcal Vaccines Market Size By Sector 2019 -2031
-
1.5.1 Public Market Size
-
1.5.2 Private Market Size
-
-
1.6 Global Pneumococcal Vaccines Market Size By Distribution Channel for 2019 -2031
-
1.6.1 Pharmacies Market Size
-
1.6.2 Community clinics Market Size
-
1.6.3 Public Health agencies Market Size
-
1.6.4 Others Market Size
-
-
1.7 Global Pneumococcal Vaccines Market Size By Conclusion for 2019 -2031
-
1.8 Global Level Competitor Analysis (Subject to Data Availability (Private Players))
-
1.9 Executive Summary Global Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
-
1.9.1 Regional Market Revenue Summary 2019 vs 2024 vs 2031
-
1.9.2 Global Market Revenue Split By Vaccine Type
-
1.9.3 Global Market Revenue Split By Product Type
-
1.9.4 Global Market Revenue Split By Sector
-
1.9.5 Global Market Revenue Split By Distribution Channel
-
1.9.6 Global Market Revenue Split By Conclusion
-
1.9.7 Global Market Dynamics, Trends, Drivers, Restraints, Opportunities
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
-
Chapter 2 North America Market Analysis
-
2.1 North America Pneumococcal Vaccines Market Size 2019 - 2031
-
2.1.1 North America Pneumococcal Vaccines Market Size By Country 2019 - 2031
-
2.1.2 North America Pneumococcal Vaccines Market Size by Vaccine Type 2019 -2031
-
2.1.2.1 North America Pneumococcal Polysaccharide Vaccines Market Size
-
2.1.2.2 North America Pneumococcal Conjugate Vaccines Market Size
-
-
2.1.3 North America Pneumococcal Vaccines Market Size by Product Type 2019 -2031
-
2.1.3.1 North America Pneumovax 23 Market Size
-
2.1.3.2 North America Synflorix Market Size
-
2.1.3.3 North America Prevnar 13 Market Size
-
2.1.3.4 North America Others Market Size
-
-
2.1.4 North America Pneumococcal Vaccines Market Size by Sector 2019 -2031
-
2.1.4.1 North America Public Market Size
-
2.1.4.2 North America Private Market Size
-
-
2.1.5 North America Pneumococcal Vaccines Market Size by Distribution Channel 2019 -2031
-
2.1.5.1 North America Pharmacies Market Size
-
2.1.5.2 North America Community clinics Market Size
-
2.1.5.3 North America Public Health agencies Market Size
-
2.1.5.4 North America Others Market Size
-
-
2.1.6 North America Pneumococcal Vaccines Market Size by Conclusion 2019 -2031
-
Chapter 3 Europe Market Analysis
-
3.1 Europe Pneumococcal Vaccines Market Size 2019 - 2031
-
3.1.1 Europe Pneumococcal Vaccines Market Size By Country 2019 - 2031
-
3.1.2 Europe Pneumococcal Vaccines Market Size by Vaccine Type 2019 -2031
-
3.1.2.1 Europe Pneumococcal Polysaccharide Vaccines Market Size
-
3.1.2.2 Europe Pneumococcal Conjugate Vaccines Market Size
-
-
3.1.3 Europe Pneumococcal Vaccines Market Size by Product Type 2019 -2031
-
3.1.3.1 Europe Pneumovax 23 Market Size
-
3.1.3.2 Europe Synflorix Market Size
-
3.1.3.3 Europe Prevnar 13 Market Size
-
3.1.3.4 Europe Others Market Size
-
-
3.1.4 Europe Pneumococcal Vaccines Market Size by Sector 2019 -2031
-
3.1.4.1 Europe Public Market Size
-
3.1.4.2 Europe Private Market Size
-
-
3.1.5 Europe Pneumococcal Vaccines Market Size by Distribution Channel 2019 -2031
-
3.1.5.1 Europe Pharmacies Market Size
-
3.1.5.2 Europe Community clinics Market Size
-
3.1.5.3 Europe Public Health agencies Market Size
-
3.1.5.4 Europe Others Market Size
-
-
3.1.6 Europe Pneumococcal Vaccines Market Size by Conclusion 2019 -2031
-
Chapter 4 Asia Pacific Market Analysis
-
4.1 Asia Pacific Pneumococcal Vaccines Market Size 2019 - 2031
-
4.1.1 Asia Pacific Pneumococcal Vaccines Market Size By Country 2019 - 2031
-
4.1.2 Asia Pacific Pneumococcal Vaccines Market Size by Vaccine Type 2019 -2031
-
4.1.2.1 Asia Pacific Pneumococcal Polysaccharide Vaccines Market Size
-
4.1.2.2 Asia Pacific Pneumococcal Conjugate Vaccines Market Size
-
-
4.1.3 Asia Pacific Pneumococcal Vaccines Market Size by Product Type 2019 -2031
-
4.1.3.1 Asia Pacific Pneumovax 23 Market Size
-
4.1.3.2 Asia Pacific Synflorix Market Size
-
4.1.3.3 Asia Pacific Prevnar 13 Market Size
-
4.1.3.4 Asia Pacific Others Market Size
-
-
4.1.4 Asia Pacific Pneumococcal Vaccines Market Size by Sector 2019 -2031
-
4.1.4.1 Asia Pacific Public Market Size
-
4.1.4.2 Asia Pacific Private Market Size
-
-
4.1.5 Asia Pacific Pneumococcal Vaccines Market Size by Distribution Channel 2019 -2031
-
4.1.5.1 Asia Pacific Pharmacies Market Size
-
4.1.5.2 Asia Pacific Community clinics Market Size
-
4.1.5.3 Asia Pacific Public Health agencies Market Size
-
4.1.5.4 Asia Pacific Others Market Size
-
-
4.1.6 Asia Pacific Pneumococcal Vaccines Market Size by Conclusion 2019 -2031
-
Chapter 5 South America Market Analysis
-
5.1 South America Pneumococcal Vaccines Market Size 2019 - 2031
-
5.1.1 South America Pneumococcal Vaccines Market Size By Country 2019 - 2031
-
5.1.2 South America Pneumococcal Vaccines Market Size by Vaccine Type 2019 -2031
-
5.1.2.1 South America Pneumococcal Polysaccharide Vaccines Market Size
-
5.1.2.2 South America Pneumococcal Conjugate Vaccines Market Size
-
-
5.1.3 South America Pneumococcal Vaccines Market Size by Product Type 2019 -2031
-
5.1.3.1 South America Pneumovax 23 Market Size
-
5.1.3.2 South America Synflorix Market Size
-
5.1.3.3 South America Prevnar 13 Market Size
-
5.1.3.4 South America Others Market Size
-
-
5.1.4 South America Pneumococcal Vaccines Market Size by Sector 2019 -2031
-
5.1.4.1 South America Public Market Size
-
5.1.4.2 South America Private Market Size
-
-
5.1.5 South America Pneumococcal Vaccines Market Size by Distribution Channel 2019 -2031
-
5.1.5.1 South America Pharmacies Market Size
-
5.1.5.2 South America Community clinics Market Size
-
5.1.5.3 South America Public Health agencies Market Size
-
5.1.5.4 South America Others Market Size
-
-
5.1.6 South America Pneumococcal Vaccines Market Size by Conclusion 2019 -2031
-
Chapter 6 Middle East and Africa Market Analysis
-
6.1 Middle East and Africa Pneumococcal Vaccines Market Size 2019 - 2031
-
6.1.1 Middle East and Africa Pneumococcal Vaccines Market Size By Country 2019 - 2031
-
6.1.2 Middle East and Africa Pneumococcal Vaccines Market Size by Vaccine Type 2019 -2031
-
6.1.2.1 Middle East and Africa Pneumococcal Polysaccharide Vaccines Market Size
-
6.1.2.2 Middle East and Africa Pneumococcal Conjugate Vaccines Market Size
-
-
6.1.3 Middle East and Africa Pneumococcal Vaccines Market Size by Product Type 2019 -2031
-
6.1.3.1 middle_east_and_africa_title} Pneumovax 23 Market Size
-
6.1.3.2 middle_east_and_africa_title} Synflorix Market Size
-
6.1.3.3 middle_east_and_africa_title} Prevnar 13 Market Size
-
6.1.3.4 middle_east_and_africa_title} Others Market Size
-
-
6.1.4 Middle East and Africa Pneumococcal Vaccines Market Size by Sector 2019 -2031
-
6.1.4.1 Middle East and Africa Public Market Size
-
6.1.4.2 Middle East and Africa Private Market Size
-
-
6.1.5 Middle East and Africa Pneumococcal Vaccines Market Size by Distribution Channel 2019 -2031
-
6.1.5.1 Middle East and Africa Pharmacies Market Size
-
6.1.5.2 Middle East and Africa Community clinics Market Size
-
6.1.5.3 Middle East and Africa Public Health agencies Market Size
-
6.1.5.4 Middle East and Africa Others Market Size
-
-
6.1.6 Middle East and Africa Pneumococcal Vaccines Market Size by Conclusion 2019 -2031
-
Only Available with Corporate User License
Chapter 7 Top 10 Countries Analysis (Only Available with Corporate User License)
-
7.1 Country 1 Market Analysis
-
7.1.1 Country 1Pneumococcal Vaccines Market Size by Vaccine Type 2019 -2031
-
7.1.2 Country 1Pneumococcal Vaccines Market Size by Product Type 2019 -2031
-
7.1.3 Country 1Pneumococcal Vaccines Market Size by Sector 2019 -2031
-
7.1.4 Country 1Pneumococcal Vaccines Market Size by Distribution Channel 2019 -2031
-
7.1.5 Country 1Pneumococcal Vaccines Market Size by Conclusion 2019 -2031
-
-
7.2 Country 2 Market Analysis
-
7.2.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.3 Country 3 Market Analysis
-
7.3.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.4 Country 4 Market Analysis
-
7.4.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.5 Country 5 Market Analysis
-
7.5.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.6 Country 6 Market Analysis
-
7.6.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.7 Country 7 Market Analysis
-
7.7.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.8 Country 8 Market Analysis
-
7.8.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.9 Country 9 Market Analysis
-
7.9.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.10 Country 10 Market Analysis
-
7.10.1 Segmentation Analysis will be provided as shown for Country 1
-
Competitor's Market Share and Revenue (Subject to Data Availability for Private Players)
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
-
8.1 Top Competitors Analysis
-
8.1.1 Top Players Ranking 2022
-
8.1.2 Global Pneumococcal Vaccines Market Revenue and Share by Manufacturers (2019-2023)
(Subject to Data Availability (Private Players))
-
8.1.3 Industry Mergers and Acquisition Analysis
-
8.1.4 New Product Launch Analysis
-
-
8.2 Company Profile (Data Subject to Availability)
-
8.2.1 Pfizer Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.1.2 Business Overview
-
8.2.1.3 Financials (Subject to data availability)
-
8.2.1.4 Product Types Specification
-
8.2.1.5 Business Strategy
-
8.2.1.6 S.W.O.TAnalysis
-
-
8.2.2 GlaxoSmithKline plc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.2.2 Business Overview
-
8.2.2.3 Financials (Subject to data availability)
-
8.2.2.4 Product Types Specification
-
8.2.2.5 Business Strategy
-
8.2.2.6 S.W.O.TAnalysis
-
-
8.2.3 Merck & Co. Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.3.2 Business Overview
-
8.2.3.3 Financials (Subject to data availability)
-
8.2.3.4 Product Types Specification
-
8.2.3.5 Business Strategy
-
8.2.3.6 S.W.O.TAnalysis
-
-
8.2.4 Serum Institute of India Pvt. Ltd
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.4.2 Business Overview
-
8.2.4.3 Financials (Subject to data availability)
-
8.2.4.4 Product Types Specification
-
8.2.4.5 Business Strategy
-
8.2.4.6 S.W.O.TAnalysis
-
-
8.2.5 Biological E. Limited
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.5.2 Business Overview
-
8.2.5.3 Financials (Subject to data availability)
-
8.2.5.4 Product Types Specification
-
8.2.5.5 Business Strategy
-
8.2.5.6 S.W.O.TAnalysis
-
-
8.2.6 Abbott
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.6.2 Business Overview
-
8.2.6.3 Financials (Subject to data availability)
-
8.2.6.4 Product Types Specification
-
8.2.6.5 Business Strategy
-
8.2.6.6 S.W.O.TAnalysis
-
-
8.2.7 Sanofi Pasteur SA
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.7.2 Business Overview
-
8.2.7.3 Financials (Subject to data availability)
-
8.2.7.4 Product Types Specification
-
8.2.7.5 Business Strategy
-
8.2.7.6 S.W.O.TAnalysis
-
-
8.2.8 Wyeth Pharmaceuticals LLC
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.8.2 Business Overview
-
8.2.8.3 Financials (Subject to data availability)
-
8.2.8.4 Product Types Specification
-
8.2.8.5 Business Strategy
-
8.2.8.6 S.W.O.TAnalysis
-
-
8.2.9 Walvax Biotechnology Co. Ltd.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.9.2 Business Overview
-
8.2.9.3 Financials (Subject to data availability)
-
8.2.9.4 Product Types Specification
-
8.2.9.5 Business Strategy
-
8.2.9.6 S.W.O.TAnalysis
-
-
8.2.10 Sk Bioscience.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.10.2 Business Overview
-
8.2.10.3 Financials (Subject to data availability)
-
8.2.10.4 Product Types Specification
-
8.2.10.5 Business Strategy
-
8.2.10.6 S.W.O.TAnalysis
-
-
8.2.11 Panacea Biotec Limited.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.11.2 Business Overview
-
8.2.11.3 Financials (Subject to data availability)
-
8.2.11.4 Product Types Specification
-
8.2.11.5 Business Strategy
-
8.2.11.6 S.W.O.TAnalysis
-
-
Chapter 9 Qualitative Analysis (Subject to Data Availability)
-
9.1 Market Drivers
-
9.2 Market Trends
-
9.3 Market Restraints
-
9.4 Market Opportunity
-
9.5 Product Life Cycle (Subject to Data Availability)
-
9.6 Industrial Chain Analysis (Subject to Data Availability)
-
9.6.1 Industry Chain Analysis
-
9.6.2 Manufacturing Cost Analysis
-
9.6.3 Consumer Preference Analysis
-
9.6.4 Supply Side Analysis
-
9.6.4.1 Raw Material Analysis
-
9.6.4.2 Raw Material Procurement Analysis
-
9.6.4.3 Raw Material Price Trend Analysis
-
-
-
9.7 Market Attractiveness Analysis
-
9.8 PESTEL Analysis
-
9.9 Porter’s Five Forces Analysis
-
9.10 Patent Analysis (Subject to Data Availability)
-
9.11 ESG Analysis
-
9.12 Technological Road Map
Segmentation Vaccine Type Analysis 2019 -2031, will provide market size split by Vaccine Type. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Vaccine Type Analysis 2019 -2031
-
10.1 Pneumococcal Polysaccharide Vaccines
-
10.1.1 Global Pneumococcal Vaccines Revenue Market Size and Share by Pneumococcal Polysaccharide Vaccines 2019 -2031
-
-
10.2 Pneumococcal Conjugate Vaccines
-
10.2.1 Global Pneumococcal Vaccines Revenue Market Size and Share by Pneumococcal Conjugate Vaccines 2019 -2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by Product Type Analysis 2019 -2031
-
11.1 Pneumovax 23
-
11.1.1 Global Pneumococcal Vaccines Revenue Market Size and Share by Pneumovax 23 2019 - 2031
-
-
11.2 Synflorix
-
11.2.1 Global Pneumococcal Vaccines Revenue Market Size and Share by Synflorix 2019 - 2031
-
-
11.3 Prevnar 13
-
11.3.1 Global Pneumococcal Vaccines Revenue Market Size and Share by Prevnar 13 2019 - 2031
-
-
11.4 Others
-
11.4.1 Global Pneumococcal Vaccines Revenue Market Size and Share by Others 2019 - 2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 12 Market Split by Sector Analysis 2019 -2031
-
12.1 Public
-
12.1.1 Global Pneumococcal Vaccines Revenue Market Size and Share by Public 2019 -2031
-
-
12.2 Private
-
12.2.1 Global Pneumococcal Vaccines Revenue Market Size and Share by Private 2019 -2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 13 Market Split by Distribution Channel Analysis 2019 -2031
-
13.1 Pharmacies
-
13.1.1 Global Pneumococcal Vaccines Revenue Market Size and Share by Pharmacies 2019 -2031
-
-
13.2 Community clinics
-
13.2.1 Global Pneumococcal Vaccines Revenue Market Size and Share by Community clinics 2019 -2031
-
-
13.3 Public Health agencies
-
13.3.1 Global Pneumococcal Vaccines Revenue Market Size and Share by Public Health agencies 2019 -2031
-
-
13.4 Others
-
13.4.1 Global Pneumococcal Vaccines Revenue Market Size and Share by Others 2019 -2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 14 Market Split by Conclusion Analysis 2019 -2031
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Pneumococcal Vaccines market
Chapter 15 Research Findings
-
15.1 Key Takeaways
-
15.2 Analyst Point of View
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
-
15.3 Assumptions and Acronyms
Sample Format of Deliverables
The Tables, Graphs/Charts are only for representative purposes and do not depict actual statistics. Purchase full Report access to actual data.
Qualitative Analysis
Research Methodology Implemented by Manjiri Kanhere and Team
- 1.1 Pneumococcal Vaccines Market Report 2024 Research Methodology
- 1.2 Systematic Research Approach
- 1.2.1 Primary Research for Pneumococcal Vaccines Market
- 1.2.1.1 Key Data from Primary
- 1.2.1.2 Primary Interviews with Experts
- 1.2.1.3 Key Industry Insights
- 1.2.1.4 Questionnaire for Pneumococcal Vaccines Market
- 1.2.1.5 Breakdown of Primaries
- 1.2.2 Secondary Research for Pneumococcal Vaccines Market
- 1.2.2.1 Key Data from Secondary
- 1.2.2.2 Paid Sources
- 1.2.2.3 Public Sources
- 1.3 Market Size Estimation for Pneumococcal Vaccines Market
- 1.3.1 Top-Down Approach
- 1.3.1.1 Analyzing Market Size by Top-Down Approach (Supply Side)
- 1.3.2 Bottom-UP Approach
- 1.3.2.1 Analyzing Market Size by Bottom-Up Approach (Demand Side)
- 1.3.1 Top-Down Approach
- 1.4 Market Breakdown and Data Triangulation
- 1.5 Research Assumptions for Pneumococcal Vaccines Market
Key Questions Answered By Pneumococcal Vaccines Market Report 2024
| Why Pneumococcal Polysaccharide Vaccines have a significant impact on Pneumococcal Vaccines market? |
| What are the key factors affecting the Pneumococcal Polysaccharide Vaccines and Pneumococcal Conjugate Vaccines of Pneumococcal Vaccines Market? |
| What is the CAGR/Growth Rate of Pneumovax 23 during the forecast period? |
| By type, which segment accounted for largest share of the global Pneumococcal Vaccines Market? |
| Which region is expected to dominate the global Pneumococcal Vaccines Market within the forecast period? |
| Segmentation Level Customization |
|
| Global level Data Customization |
|
| Region level Data Customization |
|
| Country level Data Customization |
|
| Company Level |
|
| Additional Data Analysis |
|
| Additional Qualitative Data |
|
| Additional Quantitative Data |
|
| Service Level Customization |
|
Report Format Alteration |
|
